Immunic Secures $200 Million Financing to Advance Multiple Sclerosis Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy IMUX?
Source: Newsfilter
- Successful Financing: Immunic has successfully completed an oversubscribed private placement of up to $400 million, with $200 million in initial gross proceeds, which is expected to fund its multiple sclerosis (MS) projects and facilitate the company's transition to a commercial-stage organization.
- Clinical Trial Progress: Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials for multiple sclerosis is anticipated by the end of 2026, laying the groundwork for future drug applications and market launches, with potential regulatory approval expected in 2028.
- New Drug Application Plans: The company plans to submit a New Drug Application (NDA) in mid-2027 for vidofludimus calcium in the U.S. market, which is expected to significantly enhance its competitiveness in the projected $30 billion global multiple sclerosis market.
- Board Changes: Immunic has appointed a new interim chairperson of the board and initiated a search for a new CEO with commercial expertise to support the company's further development in the multiple sclerosis field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.160
Low
3.00
Averages
4.25
High
8.00
Current: 1.160
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic Secures Key European Patent for Vidofludimus
- Patent Protection Extended: Immunic has secured European patent EP3713554, covering all label-relevant dosing regimens for vidofludimus calcium, expected to provide protection in Europe until 2038, with potential extension to 2043 through a Supplementary Protection Certificate, significantly enhancing market exclusivity.
- Multi-Layered IP Strategy: This patent complements the one granted by the USPTO in 2023, creating a robust multi-layered protection for vidofludimus calcium, ensuring competitive advantage across various indications and formulations, thereby strengthening the company's position in the biotechnology sector.
- Clinical Trial Progress: Vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with earlier phase 2 trials demonstrating significant efficacy in reducing brain lesions and improving disability in patients, which is expected to drive future market demand.
- Future Growth Potential: Immunic plans to continue expanding its patent portfolio with the goal of maximizing long-term exclusivity, and as potential regulatory approvals approach, the market outlook for vidofludimus calcium will further strengthen, potentially leading to substantial revenue growth for the company.
See More
Immunic Secures Key European Patent for Vidofludimus
- Patent Protection Extended: Immunic's European patent EP3713554 grants protection for its lead asset vidofludimus calcium until 2038, with potential extension to 2043 through a Supplementary Protection Certificate, thereby securing its market exclusivity.
- Multi-Layered IP Strategy: The patent broadly covers all dosing regimens for vidofludimus and its salts, solvates, and free acid forms, enhancing the company's competitive position in treating neurologic and gastrointestinal diseases through a robust intellectual property framework.
- Clinical Trial Progress: Vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with earlier phase 2 trials demonstrating significant efficacy in reducing brain lesions and improving disability, with top-line data expected by the end of 2026.
- Significant Market Potential: As a new chemical entity, vidofludimus calcium's unique mechanism combines neuroprotective, anti-inflammatory, and antiviral effects, positioning Immunic for strong long-term growth in the global market.
See More
Immunic, Inc. Participates in Investor Conferences
- Investor Conference Participation: Immunic, Inc. will participate in several investor conferences in March, with management including Dr. Vitt, Mr. Tardio, and VP of Investor Relations Jessica Breu engaging in one-on-one meetings to enhance investor relations and transparency.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective and anti-inflammatory effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological and gastrointestinal diseases.
- Future Development Directions: The company is also developing new molecules like IMU-856 and IMU-381, with the former aimed at restoring intestinal barrier function and the latter targeting neurological and autoimmune diseases, indicating Immunic's ongoing innovation and market expansion strategy in the biotech sector.
See More
Immunic, Inc. to Participate in Investor Conferences
- Investor Conference Schedule: Immunic, Inc. will participate in the Leerink Partners Global Healthcare Conference from March 8-11, where CEO Daniel Vitt, Ph.D., and COO Jason Tardio will engage in a fireside chat on March 11, potentially increasing investor interest and enhancing company visibility.
- One-on-One Meeting Opportunities: During the conference, Immunic's executive team will hold one-on-one meetings with investors, providing in-depth discussions about the business and products, which could bolster investor confidence and facilitate potential capital inflows.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in Phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's future market performance.
- New Therapy Development: New molecules like IMU-856 and IMU-381 are under development to address various neurological and gastrointestinal diseases, and successful launches will further solidify Immunic's leadership in the biotechnology sector and drive long-term growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of CRWD stock, as their ratings and price targets can directly impact short-term stock performance and investor confidence.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, has been published on Benzinga's analyst ratings page, providing investors with a holistic view of the market.
- Market Reaction Potential: Changes in analyst ratings may trigger market volatility, prompting investors to closely monitor these shifts to timely adjust their investment strategies and risk management practices.
See More
Immunic Reports FY 2025 Earnings with Positive Cash Outlook
- Earnings Highlights: Immunic reported a FY 2025 GAAP EPS of -$0.62, beating expectations by $0.05, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, Immunic had approximately $15.5 million in cash and cash equivalents, providing a short-term liquidity buffer that ensures operational stability in the coming months.
- Funding Strategy: The company raised approximately $187 million in net cash from a private placement in February 2026, enabling it to fund operations into late 2027, which bolsters market confidence in its sustainability.
- Market Reaction: Following the announcement of a $400 million private placement, Immunic's stock price rose, reflecting investor optimism about the company's future, particularly in light of leadership transitions.
See More
Immunic Secures Key European Patent for Vidofludimus
- Patent Protection Extended: Immunic has secured European patent EP3713554, covering all label-relevant dosing regimens for vidofludimus calcium, expected to provide protection in Europe until 2038, with potential extension to 2043 through a Supplementary Protection Certificate, significantly enhancing market exclusivity.
- Multi-Layered IP Strategy: This patent complements the one granted by the USPTO in 2023, creating a robust multi-layered protection for vidofludimus calcium, ensuring competitive advantage across various indications and formulations, thereby strengthening the company's position in the biotechnology sector.
- Clinical Trial Progress: Vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with earlier phase 2 trials demonstrating significant efficacy in reducing brain lesions and improving disability in patients, which is expected to drive future market demand.
- Future Growth Potential: Immunic plans to continue expanding its patent portfolio with the goal of maximizing long-term exclusivity, and as potential regulatory approvals approach, the market outlook for vidofludimus calcium will further strengthen, potentially leading to substantial revenue growth for the company.
See More
Immunic Secures Key European Patent for Vidofludimus
- Patent Protection Extended: Immunic's European patent EP3713554 grants protection for its lead asset vidofludimus calcium until 2038, with potential extension to 2043 through a Supplementary Protection Certificate, thereby securing its market exclusivity.
- Multi-Layered IP Strategy: The patent broadly covers all dosing regimens for vidofludimus and its salts, solvates, and free acid forms, enhancing the company's competitive position in treating neurologic and gastrointestinal diseases through a robust intellectual property framework.
- Clinical Trial Progress: Vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with earlier phase 2 trials demonstrating significant efficacy in reducing brain lesions and improving disability, with top-line data expected by the end of 2026.
- Significant Market Potential: As a new chemical entity, vidofludimus calcium's unique mechanism combines neuroprotective, anti-inflammatory, and antiviral effects, positioning Immunic for strong long-term growth in the global market.
See More
Immunic, Inc. Participates in Investor Conferences
- Investor Conference Participation: Immunic, Inc. will participate in several investor conferences in March, with management including Dr. Vitt, Mr. Tardio, and VP of Investor Relations Jessica Breu engaging in one-on-one meetings to enhance investor relations and transparency.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective and anti-inflammatory effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological and gastrointestinal diseases.
- Future Development Directions: The company is also developing new molecules like IMU-856 and IMU-381, with the former aimed at restoring intestinal barrier function and the latter targeting neurological and autoimmune diseases, indicating Immunic's ongoing innovation and market expansion strategy in the biotech sector.
See More
Immunic, Inc. to Participate in Investor Conferences
- Investor Conference Schedule: Immunic, Inc. will participate in the Leerink Partners Global Healthcare Conference from March 8-11, where CEO Daniel Vitt, Ph.D., and COO Jason Tardio will engage in a fireside chat on March 11, potentially increasing investor interest and enhancing company visibility.
- One-on-One Meeting Opportunities: During the conference, Immunic's executive team will hold one-on-one meetings with investors, providing in-depth discussions about the business and products, which could bolster investor confidence and facilitate potential capital inflows.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in Phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's future market performance.
- New Therapy Development: New molecules like IMU-856 and IMU-381 are under development to address various neurological and gastrointestinal diseases, and successful launches will further solidify Immunic's leadership in the biotechnology sector and drive long-term growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of CRWD stock, as their ratings and price targets can directly impact short-term stock performance and investor confidence.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, has been published on Benzinga's analyst ratings page, providing investors with a holistic view of the market.
- Market Reaction Potential: Changes in analyst ratings may trigger market volatility, prompting investors to closely monitor these shifts to timely adjust their investment strategies and risk management practices.
See More
Immunic Reports FY 2025 Earnings with Positive Cash Outlook
- Earnings Highlights: Immunic reported a FY 2025 GAAP EPS of -$0.62, beating expectations by $0.05, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, Immunic had approximately $15.5 million in cash and cash equivalents, providing a short-term liquidity buffer that ensures operational stability in the coming months.
- Funding Strategy: The company raised approximately $187 million in net cash from a private placement in February 2026, enabling it to fund operations into late 2027, which bolsters market confidence in its sustainability.
- Market Reaction: Following the announcement of a $400 million private placement, Immunic's stock price rose, reflecting investor optimism about the company's future, particularly in light of leadership transitions.
See More
